Direct cardiac actions of erythropoietin (EPO): Effects on cardiac contractility, BNP secretion and ischaemia/reperfusion injury

Clinical Science

Volumn 114, Issue 3-4, 2008, Pages 293-304

  Piuhola, Jarkko ^a,b   Kerkelä, Risto ^c   Keenan, Jacqueline I ^a   Hampton, Mark B ^a   Richards, A Mark ^a   Pemberton, Chris J ^a  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b UNIVERSITY OF OULU   (Finland)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Cardiac ischaemia; Endothelin; Erythropoietin (EPO); Ischaemia reperfusion injury; Natriuretic peptide

Indexed keywords

BOSENTAN; BRAIN NATRIURETIC PEPTIDE; CREATINE KINASE; DNA; ENDOTHELIN 1; ERYTHROPOIETIN; JANUS KINASE 2; STAT3 PROTEIN; TRANSCRIPTION FACTOR GATA 4; ENDOTHELIN RECEPTOR; RECOMBINANT ERYTHROPOIETIN; STAT3 PROTEIN, RAT; SULFONAMIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA BINDING; ENZYME RELEASE; HEART MUSCLE CONTRACTILITY; HEART MUSCLE ISCHEMIA; HEART PERFUSION; MALE; NICK END LABELING; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; RAT; REPERFUSION INJURY; ANIMAL; DOSE RESPONSE; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HEART; HEART CONTRACTION; HUMAN; METABOLISM; PATHOPHYSIOLOGY; PERFUSION; PHOSPHORYLATION; SECRETION; SPRAGUE DAWLEY RAT; STIMULATION;

ANIMALS; APOPTOSIS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; ERYTHROPOIETIN, RECOMBINANT; HEART; HUMANS; JANUS KINASE 2; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; NATRIURETIC PEPTIDE, BRAIN; PERFUSION; PHOSPHORYLATION; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, ENDOTHELIN; STAT3 TRANSCRIPTION FACTOR; STIMULATION, CHEMICAL; SULFONAMIDES;

EID: 38949181122     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20070229     Document Type: Article

References (39)

1. Smith, K. J., Bleyer, A. J., Little, W. C. and Sane, D. C. (2003) The cardiovascular effects of erythropoietin. Cardiovasc. Res. 59, 538-548
2. Sterin-Borda, L., Barcelo, A. C. and Bozzini, C. E. (2003) Erythropoietin improves cardiac contractility in post-hypoxic mice. Br. J. Haematol. 121, 180-186
3. Cai, Z., Manalo, D. J., Wei, G. et al. (2003) Hearts from rodents exposed to intermittent hypoxia or erythropoietin are protected against ischemia-reperfusion injury. Circulation 108, 79-85
4. Moon, C., Krawczyk, M., Ahn, D. et al. (2003) Erythropoietin reduces myocardial infarction and left ventricular functional decline after coronary artery ligation in rats. Proc. Natl. Acad. Sci. U.S.A. 100, 11612-11617
5. Parsa, C. J., Matsumoto, A., Kim, J. et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J. Clin. Invest. 112, 999-1007
6. Parsa, C. J., Kim, J., Riel, R. U. et al. (2004) Cardioprotective effects of erythropoietin in the reperfused ischemic heart: a potential role for cardiac fibroblasts. J. Biol. Chem. 279, 20655-20662
7. Bullard, A. J. and Yellon, D. M. (2005) Chronic erythropoietin treatment limits infarct-size in the myocardium in vitro. Cardiovasc. Drugs Ther. 19, 333-336
8. Lipsic, E., Schoemaker, R. G., van der Meer, P., Voors, A. A., van Veldhuisen, D. J. and van Gilst, W. H. (2006) Protective effects of erythropoietin in cardiac ischemia: from bench to bedside. J. Am. Coll. Cardiol. 48, 2161-2171
9. Mancini, D. M., Katz, S. D., Lang, C. C., LaManca, J., Hudaihed, A. and Androne, A. S. (2003) Effect of erythropoietin on exercise capacity in patients with moderate to severe chronic heart failure. Circulation 107, 294-299
10. Palazzuoli, A., Silverberg, D., Iovine, F. et al. (2006) Erythropoietin improves anemia exercise tolerance and renal function and reduces B-type natriuretic peptide and hospitalization in patients with heart failure and anemia. Am. Heart J. 152, e9-e15
11. Silverberg, D. S., Wexler, D., Sheps, D. et al. (2001) The effect of correction of mild anemia in severe, resistant congestive heart failure using subcutaneous erythropoietin and intravenous iron: a randomized controlled study. J. Am. Coll. Cardiol. 37, 1775-1780
12. Bode-Boger, S. M., Boger, R. H., Kuhn, M., Radermacher, J. and Frolich, J. C. (1996) Recombinant human erythropoietin enhances vasoconstrictor tone via endothelin-1 and constrictor prostanoids. Kidney Int. 50, 1255-1261
13. Carlini, R. G., Dusso, A. S., Obialo, C. I., Alvarez, U. M. and Rothstein, M. (1993) Recombinant human erythropoietin (rHuEPO) increases endothelin-1 release by endothelial cells. Kidney Int. 43, 1010-1014
14. Ksiazek, A., Zaluska, W. T. and Ksiazek, P. (2001) Effect of recombinant human erythropoietin on adrenergic activity in normotensive hemodialysis patients. Clin. Nephrol. 56, 104-110
15. Eggena, P., Willsey, P., Jamgotchian, N. et al. (1991) Influence of recombinant human erythropoietin on blood pressure and tissue renin-angiotensin systems. Am. J. Physiol. 261, E642-E646
16. Pemberton, C. J., Raudsepp, S. D., Yandle, T. G., Cameron, V. A. and Richards, A. M. (2005) Plasma cardiotrophin-1 is elevated in human hypertension and stimulated by ventricular stretch. Cardiovasc. Res. 68, 109-117
17. Piuhola, J., Szokodi, I., Kinnunen, P. et al. (2003) contributes to the Frank-Starling response in hypertrophic rat hearts. Hypertension 41, 93-98
18. Tenhunen, O., Sármán, B., Kerkelä, R. et al. (2004) Mitogen-activated protein kinases p38 and ERK 1/2 mediate the wall stress-induced activation of GATA-4 binding in adult heart. J. Biol. Chem. 279, 24852-24860
19. Szokodi, I., Kinnunen, P., Tavi, P., Weckström, M., Tóth, M. and Ruskoaho, H. (1998) Evidence for cAMP-independent mechanisms mediating the effects of adrenomedullin, a new inotropic peptide. Circulation 97, 1062-1070
20. Ramakrishnan, R., Cheung, W. K., Wacholtz, M. C., Minton, N. and Jusko, W. J. (2004) Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after single and multiple doses in healthy volunteers. J. Clin. Pharmacol. 44, 991-1002
21. Noe, G., Schrezenmeier, H., Rich, I. N. and Kubanck, B. (1994) Circulating erythropoietin levels in pathophysiological conditions. Ann. N.Y. Acad. Sci. 718, 94-102
22. Porat, O., Neumann, D., Zamir, O., et al. (1996) Erythropoietin stimulates atrial natriuretic peptide secretion from adult rat cardiac atrium. J. Pharmacol. Exp. Ther. 276, 1162-1168
23. Ruskoaho, H. (2003) Cardiac hormones as diagnostic tools in heart failure. Endocr. Rev. 24, 341-356
24. Troughton, R. W., Frampton, C. M., Yandle, T. G., Espiner, E. A., Nicholls, M. G. and Richards, A. M. (2000) Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet 355, 1126-1130
25. Kumagai, J., Yorioka, N., Kawanishi, H. et al. (1999) Relationship between erythropoietin and chronic heart failure in patients on chronic hemodialysis. J. Am. Soc. Nephrol. 10, 2407-2411
26. Fyhrquist, F., Karppinen, K., Honkanen, T., Saijonmaa, O. and Rosenlöf, K. (1989) High serum erythropoietin levels are normalized during treatment of congestive heart failure with enalapril. J. Intern. Med. 226, 257-260
27. Calvillo, L., Latini, R., Kajstura, J. et al. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc. Natl. Acad. Sci. U.S.A. 100, 4802-4806
28. Cai, Z. and Semenza, G. L. (2004) Phosphatidylinositol-3-kinase signaling is required for erythropoietin mediated acute protection against myocardial ischemia reperfusion injury. Circulation 109, 2050-2053
29. van deer Meer, P., Lipsic, E., Henning, R. H. et al. (2004) Erythropoietin improves left ventricular function and coronary flow in an experimental model of ischemia-reperfusion injury. Eur. J. Heart Failure 6, 853-859
30. Hanlon, P. R., Fu, P., Wright, G. L., Steenbergen, C., Arcasoy, M. O. and Murphy, E. (2005) Mechanisms of erythropoietin-mediated cardioprotection during ischemia-reperfusion injury: role of protein kinase C and phosphatidylinositol 3-kinase signaling. FASEB J. 19, 1323-1335
31. Nishikimi, T., Maeda, N. and Matsuoka, H. (2006) The role of natriuretic peptides in cardioprotection. Cardiovasc. Res. 69, 318-328
32. Pikkarainen, S., Tokola, H., Kerkelä, R. and Ruskoaho, H. (2004) GATA transcription factors in the developing and adult heart. Cardiovasc Res 63, 196-207
33. Aries, A., Paradis, P., Lefebvre, C., Schwartz, R. J. and Nemer, M. (2004) Essential role of GATA-4 in cell survival and drug-induced cardiotoxicity. Proc. Natl. Acad. Sci. U.S.A. 101, 6975-6980
34. Massoudy, P., Zahler, S., Kupatt, C., Reder, E., Becker, B. F. and Gerlach, E. (1997) Cardioprotection by cyclosporine A in experimental ischemia and reperfusion: evidence for a nitric oxide-dependent mechanism mediated by endothelin. J. Mol. Cell Cardiol. 29, 535-544
35. Oka, T., Maillet, M., Watt, A. J. et al. (2006) Cardiac-specific deletion of GATA-4 reveals its requirement for hypertrophy, compensation, and myocyte viability. Circ. Res. 98, 837-845
36. Wang, J., Paradis, P., Aries, A. et al. (2005) Convergence of protein kinase C and JAK-STAT signaling on transcription factor GATA-4. Mol. Cell Biol. 22, 9829-9844
37. Xuan, Y. T., Guo, Y., Han, H., Zhu, Y. and Bolli, R. (2001) An essential role of the JAK-STAT pathway in ischemic preconditioning, Proc. Natl. Acad. Sci. U.S.A. 98, 9050-9055
38. Liu, H. R., Gao, E., Hu, A. et al. (2005) Role of Omi/HtrA2 in apoptotic cell death after myocardial ischemia and reperfusion. Circulation 111, 90-96
39. Yuan, J., Lipinski, M. and Degterev, A. (2003) Diversity in the mechanisms of neuronal cell death. Neuron 40, 401-413